About this trial
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, which is associated with hormonal imbalances, dyslipidemia, chronic inflammation, and increased oxidative stress, and can increase the risk of cardiovascular and metabolic diseases. Evidence suggests that nutritional interventions play an important role in improving metabolic outcomes in these patients.
This study is a randomized, triple-blind, controlled clinical trial designed to investigate the effect of a light fasting diet combined with magnesium supplementation on lipid profile, lipid peroxidation (malondialdehyde), and C-reactive protein (CRP) levels in women with PCOS. In this study, 46 eligible women were randomly divided into two groups receiving a light fasting diet with magnesium supplementation or placebo, and changes in biochemical and anthropometric indices were evaluated before and after 8 weeks of intervention.
Eligibility criteria
Qualifiers
People between the ages of 19 and 65
People with a body mass index (BMI) ≤ 25
Diagnosis of polycystic ovary syndrome by a specialist based on the Rotterdam criteria
Disqualifiers
Failure of the participant to cooperate during the study
Use of drug therapy that affects carbohydrate or fat metabolism (including oral contraceptives, insulin sensitizers, antiepileptic drugs, antipsychotics, statins, and fish oil) within the past 6 months.
Planning for pregnancy, pregnant, or breastfeeding
In the perimenopausal stage
Trial design
Treatments tested in this trial
- Light fasting
- Magnesium supplementation
- Light fasting
- Placebo
Treatment groups
Locations
Sponsors and collaborators
Behnood Abbasi
Lead sponsor
Science & Research Islamic Azad University Branch Khozestan
Sponsor institution